Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-19Clinical Trial Update: Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML [Phase 1]
Phase 1 trial of uproleselan with pre-transplant conditioning in hematopoietic stem cell transplantation for acute myeloid leukemia has been…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia [Phase 1]
Phase 1 study evaluating revumenib in combination with chemotherapy for relapsed/refractory acute leukemias has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Psychological Intervention Mobile App for Patients With AML [NA]
A completed clinical trial evaluating a psychological intervention mobile app designed to support patients with acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 study of MEN1112 intravenous infusion in relapsed or refractory acute myeloid leukemia was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia [EARLY_Phase 1]
An early-phase clinical trial is evaluating the safety and potential efficacy of NK520 in pediatric patients with relapsed/refractory acute …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study evaluating lanraplenib in combination with gilteritinib in FLT3-mutated re…
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Haploidentical Donor vs mMUD in Hematological Malignancies [Phase 2, Phase 3]
A Phase 2/3 clinical trial comparing haploidentical donor transplantation to matched unrelated donor transplantation in hematologic malignan…
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia [Phase 2]
This Phase 2 trial update reports results on using FLT PET/CT to measure response in patients with previously untreated acute myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Effect of Food on Blood Levels of ASTX727 [Phase 1]
Phase 1 trial evaluating the impact of food on plasma levels of ASTX727 (decitabine/cedazuridine) in patients with myelodysplastic syndromes…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias [Phase 1, Phase 2]
An early-phase study of escalating doses of AT9283 for various leukemias has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) [Phase 1]
This Phase 1 study evaluating ASTX660 alone and in combination with ASTX727 in relapsed/refractory acute myeloid leukemia has been terminate…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms [Phase 1]
The Phase 1 study of TAS1553 in subjects with relapsed or refractory acute myeloid leukemia and other myeloid neoplasms has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 trial evaluated arsenic trioxide in combination with cyclophosphamide in patients with relapsed/refractory acute myeloid leukemia.…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial results for Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia have been …
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies [Phase 1]
Phase 1 study of AMG 330 in adults with myeloid malignancies, including relapsed/refractory acute myeloid leukemia and MRD-positive AML, has…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) [Phase 3]
A Phase 3 trial comparing idarubicin plus cytarabine (IA) versus IA plus cladribine (IAC) as induction therapy for newly diagnosed acute mye…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy [Phase 2]
Phase 2 study of Cusatuzumab plus Azacitidine in newly diagnosed acute myeloid leukemia patients who are not candidates for intensive chemot…
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 [Phase 2]
Phase 2 clinical trial evaluating upfront hematopoietic stem cell transplantation in adults aged 65-75 with acute myeloid leukemia has compl…
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression [Phase 3]
Phase 3 trial evaluating haploidentical allogeneic peripheral blood transplantation with analysis of checkpoint immune regulator expression;…
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2, Phase 3]
This clinical trial update reports results from Phase 2 and Phase 3 studies evaluating azacitidine with or without nivolumab or midostaurin,…
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
The document reports results from a French temporary utilization authorization study of first-line acute myeloid leukemia patients ineligibl…
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS [Phase 1]
Phase 1 trial assessing safety and potential efficacy of allogeneic NK cell infusions in adults with relapsed/refractory acute myeloid leuke…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders [Phase 1]
Phase 1 trial update on T-allo10 for hematopoietic stem cell transplantation in various blood disorders; the NCT03198234 study sponsored by …
-
CLINICAL_TRIALS trial_result · 2024-07-17Clinical Trial Update: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia [Phase 2]
This Phase 2 trial evaluated tipifarnib in patients with chronic myelomonocytic leukemia and other myelodysplastic/myeloproliferative neopla…
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS [Phase 2]
Phase 2 clinical trial update comparing reduced-intensity conditioning and myeloablative conditioning for hematopoietic stem cell transplant…